Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 386

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

A multigene predictor of outcome in glioblastoma

Open access
Colman, H., Zhang, L., Sulman, E. P., McDonald, J. M., Shooshtari, N. L., Rivera, A., Popoff, S., Nutt, C. L., Louis, D. N., Cairncross, J. G., Gilbert, M. R., Phillips, H. S., Mehta, M. P., Chakravarti, A., Pelloski, C. E., Bhat, K., Feuerstein, B. G., Jenkins, R. B., Aldape, K.·2010·Neuro-Oncology

Abstract

Only a subset of patients with newly diagnosed glioblastoma (GBM) exhibit a response to standard therapy. To date, a biomarker panel with predictive power to distinguish treatment sensitive from treatment refractory GBM tumors does not exist. An analysis was performed using GBM microarray data from 4 independent data sets. An examination of the genes consistently associated with patient outcome, revealed a consensus 38-gene survival set. Worse outcome was associated with increased expression of genes associated with mesenchymal differentiation and angiogenesis. Application to formalin fixed-paraffin embedded (FFPE) samples using real-time reverse-transcriptase polymerase chain reaction assays resulted in a 9-gene subset which appeared robust in these samples. This 9-gene set was then validated in an additional independent sample set. Multivariate analysis confirmed that the 9-gene set was an independent predictor of outcome after adjusting for clinical factors and methylation of the methyl-guanine methyltransferase promoter. The 9-gene profile was also positively associated with markers of glioma stem-like cells, including CD133 and nestin. In sum, a multigene predictor of outcome in glioblastoma was identified which appears applicable to routinely processed FFPE samples. The profile has potential clinical application both for optimization of therapy in GBM and for the identification of novel therapies targeting tumors refractory to standard therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/nop007

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 386

Metadata

Authors
Colman, H., Zhang, L., Sulman, E. P., McDonald, J. M., Shooshtari, N. L., Rivera, A., Popoff, S., Nutt, C. L., Louis, D. N., Cairncross, J. G., Gilbert, M. R., Phillips, H. S., Mehta, M. P., Chakravarti, A., Pelloski, C. E., Bhat, K., Feuerstein, B. G., Jenkins, R. B., & Aldape, K.
Venue
Neuro-Oncology
Published
2009-10-20
Volume
12
Issue
1
Pages
49-57
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2119000874
Cited by
386
References
38
FWCI
15.63
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A multigene predictor of outcome in glioblastoma. https://app.cochat.ai/papers/10.1093/neuonc/nop007
The paper
Colman, H., Zhang, L., Sulman, E. P., McDonald, J. M., Shooshtari, N. L., Rivera, A., Popoff, S., Nutt, C. L., Louis, D. N., Cairncross, J. G., Gilbert, M. R., Phillips, H. S., Mehta, M. P., Chakravarti, A., Pelloski, C. E., Bhat, K., Feuerstein, B. G., Jenkins, R. B., & Aldape, K. (2010). A multigene predictor of outcome in glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/nop007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.